Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171740 | 0.88 | CHRM2 (0.43) | CYP19A1ABCB1CHRM2CHRM4CHRM1 | |
| SCHEMBL22122699 | 0.87 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL28655508 | 0.82 | CHRM2 (0.36) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30987473 | 0.82 | CHRM2 (0.36) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30987437 | 0.82 | CHRM2 (0.36) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL31602245 | 0.82 | CHRM2 (0.36) | CYP19A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL28208008 | 0.80 | NAAA (0.49) | NAAACYP19A1NLRP3ALDH1A1 | |
| SCHEMBL2172992 | 0.80 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18334321 | 0.79 | CYP19A1 (0.51) | SLC18A3NAAACYP19A1CHRM2CHRM4 | |
| SCHEMBL31459830 | 0.79 | CYP19A1 (0.51) | SLC18A3NAAACYP19A1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030068295-A1 | Odor neutralizers | SYMRISE AG (DE) | 2003-04-10 | — | — | US | claimed |
| EP-1239890-A2 | ODOR NEUTRALIZERS | HAARMANN & REIMER GMBH (DE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001043784-A2 | ODOR NEUTRALIZERS | HAARMANN & REIMER GMBH (DE) | 2001-06-21 | — | — | WO | claimed |
| EP-3661567-A1 | SCENT SWITCH DEVICE | Symrise AG (DE) | 2020-06-10 | — | — | EP | disclosed |
| US-20200171194-A1 | SCENT SWITCH DEVICE | SYMRISE AG (DE) | 2020-06-04 | — | — | US | disclosed |
| WO-2019025007-A1 | SCENT SWITCH DEVICE | SYMRISE AG (DE) | 2019-02-07 | — | — | WO | disclosed |
| EP-2346535-A1 | MALODOR CONTROL SYSTEM | The Procter & Gamble Company (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010053891-A1 | MALODOR CONTROL SYSTEM | THE PROCTER & GAMBLE COMPANY (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100111889-A1 | Malodor Control System | PROCTER & GAMBLE COMPANY, THE | 2010-05-06 | — | — | US | disclosed |
| US-7157411-B2 | Odor neutralizers | SYMRISE GMBH & CO. KG (DE) | 2007-01-02 | — | — | US | disclosed |
| EP-1239890-B1 | ODOR NEUTRALIZERS | SYMRISE GMBH & CO KG (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030068295-A1 | Odor neutralizers | SYMRISE AG (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1239890-A2 | ODOR NEUTRALIZERS | HAARMANN & REIMER GMBH (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001043784-A2 | ODOR NEUTRALIZERS | HAARMANN & REIMER GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030068295-A1 | Odor neutralizers | OXER1, OR51E2, OR10J3 | SLC18A3 3843/4885NAAA 1469/4885CYP19A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.